It is currently Wed Nov 25, 2015 12:20 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.


Trial drug for treatment of fatigue in MS. Don't know what their other MS drugs are or what phase they are in.

MultiCell to Present Company's Portfolio of Novel Drug Candidates at BIO 2006 Conference; Company President Dr. Stephen Chang to Discuss Novel Therapeutic Candidates Targeting Multiple Sclerosis, Diabetes and Other Medical Needs

SAN DIEGO--(BUSINESS WIRE)--April 10, 2006 - MultiCell Technologies, Inc. (OTCBB:MCET), developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and ...
Read more : MCT-125 | Views : 1286 | Replies : 0


News about NeuroVax at the AAN. Sounds promising but I didn't read anything about disability progression.

The Immune Response Corporation's NeuroVax Restores FOXP3+ T-Cell Levels Believed to Help in Multiple Sclerosis
Oral Presentation at American Academy of Neurology

CARLSBAD, C.A. -- April 10, 2006 -- The Immune Response Corporation (OTCBB:IMNR.OB) announced that its T-cell receptor peptide vaccine candidate, NeuroVax™, induces increased FOXP3 expression resulting in re-establishment of normal levels of the FOXP3+ regulatory T-cells believed ...
Read more : NeuroVax | Views : 1812 | Replies : 0

Extension study FTY720 results

Phase II Data For FTY720 Shows Sustained Efficacy And Good Tolerability Over 18 Months In Patients With Relapsing Multiple Sclerosis (MS)

Data from the extension of a Phase II study to 18 months support the significant effects of FTY720 (fingolimod), a novel once-daily oral compound in development for treatment of relapsing-remitting multiple sclerosis (MS). More than two million people worldwide are estimated to suffer from MS, which is the leading cause of neurological disability in ...
Read more : Extension study FTY720 results | Views : 1655 | Replies : 0

High dose cyclophosphamide

Not a nice therapy, but looks like it helps if used early and agressively. On a side note, it's kind of sad that they are still discovering new stuff about this drug. It's been used at least experimentally in MS since the late 60's I believe. Better late than never?

High Dose Cyclophosphamide Achieves Rapid Clinical Improvements in Early, Aggressive Multiple Sclerosis: Presented at AAN

April 6, 2006 -- Preliminary data from a study utilizing ...
Read more : High dose cyclophosphamide | Views : 1315 | Replies : 0

Higher dose of Copaxone in clinical trials

I guess it's good news, just not as exciting as a treatment that might actually be a breakthrough. I'm not complaining though...and now there's something new to add to the phase III section of the list.

Teva Announces That Higher Dose of Copaxone Showed Increased Efficacy in Multiple Sclerosis (MS)

BUSINESS WIRE - April 5, 2006 - A new, higher dose of Copaxone (glatiramer acetate injection) showed promising results in the treatment of patients with ...
Read more : Higher dose of Copaxone in clinical trials | Views : 1404 | Replies : 0

Avonex plus Doxycycline trial preliminary results

An abstract from the AAN meeting about the combination trial of doxycycline and Avonex. The preliminary, small sample results look promising.

Combination Therapy with Intramuscular Interferon Beta-1a and Oral Doxycycline in Patients with Multiple Sclerosis: An Open-Label Trial

Alireza Minagar, J. Steven Alexander, Rhonda Brooks, Roger E. Kelley, Robert N. Schwendimann, Eduardo Gonzalez-Toledo, Dana Merrill Bryan, Shreveport, LA

OBJECTIVE: To determine the safety, tolerability, and efficacy of doxycycline combined with intramuscular (IM) interferon beta-1a (IFNb-1a) ...
Read more : Avonex plus Doxycycline trial preliminary results | Views : 4985 | Replies : 23

BHT-3009 Meeting/Info Results

There's some great info about the drug below.

Bayhill Therapeutics, Inc. Research on Multiple Sclerosis Chosen as One of the Meeting's Scientific Program Highlights at the 58th Annual Meeting of the American Academy of Neurology
4/4/2006 8:41:00 AM EST

Bayhill Therapeutics will make two presentations today at the 58th Annual Meeting of the American Academy of Neurology in San Diego in connection with development of the company's lead drug candidate, BHT-3009, for the treatment of ...
Read more : BHT-3009 Meeting/Info Results | Views : 1365 | Replies : 0

Better Rebif

A new and improved Rebif. Can't really see if it actually does anything better for the disease.

It's funny that as new therapies are on the horizon that Biogen published info yesterday that Avonex after first CIS substantially delayed dx of MS and now Serono has come up with a better Rebif.

The only interesting part of the article was "Serono also is taking a leading role in developing an understanding of the role of ...
Read more : Better Rebif | Views : 1475 | Replies : 1


It might as well be written in Chinese, but it looks as if another company is looking at possbible therapies for MS and other neurological diseases - which must be good.
Read more : KineMed | Views : 1380 | Replies : 1

Completed Phase II trial of oral IFN-alpha

Interesting that this talks about a completed phase II trial of an oral treatment. I hope if they do another trial it will be phase III.

Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis.

J Interferon Cytokine Res. 2006 Mar;26(3):150-5.
Brod SA, Nguyen M, Hood Z, Shipley GL.
Department of Neurology, University of Texas-Houston, Health Science Center (UTHHSC), Houston, TX 77030, USA.

In a phase II trial ...
Read more : Completed Phase II trial of oral IFN-alpha | Views : 1678 | Replies : 2


Login  •  Register


Total posts 228531 • Total topics 24178 • Total members 15466

Contact us | Terms of Service